Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...
June 2024
Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Luye Pharma Submits Market Approval Application for Rivastigmine Patch in Japan
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...
HutchMed Initiates Phase I Clinical Trial for HMPL-506 in Hematologic Malignancies
HutchMed (HKG: 0013, NASDAQ: HCM) has announced the commencement of a Phase I clinical study...
Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research...
Sino Biopharmaceutical Presents FS222 Phase I Results at ASCO Annual Meeting
Sino Biopharmaceutical Ltd (HKG: 1177), a prominent biopharmaceutical company in China, has presented updates from...
Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
3SBio Secures Exclusive Licensing Agreement for Seven Drug Candidates from Subsidiary
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed...
Rightongene Bio Receives NMPA Approval for BCR-ABL P210 Fusion Gene Detection Kit
Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a biopharmaceutical company based in China, has announced...
WuXi Biologics Expands Manufacturing Capacity with New Bioreactors at Hangzhou Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
J&J’s Tecvayli Shows Promising Response Rates in Multiple Myeloma Trial
Johnson & Johnson (J&J; NYSE: JNJ) has reported updates from a Phase I/II clinical trial...
Jiangsu Hengrui Pharmaceuticals Receives FDA Form 483 Following Inspection Discrepancies
The U.S. Food and Drug Administration (FDA) has issued a Form 483 to Jiangsu Hengrui...
Cloudbreak Pharma Files for Hong Kong IPO with Focus on Ophthalmic Innovations
Cloudbreak Pharma Inc., a Cayman Islands-registered pharmaceutical company, has filed for an initial public offering...
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong...
China’s NHC Launches Health Literacy Plan to Shift Focus to Preventative Healthcare
China’s National Health Commission (NHC), in collaboration with two other bureaus, has unveiled the “All-Citizen...
Bristol Myers Squibb’s Breyanzi Shows Promising Results in Three Lymphoma Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has announced results from three distinct clinical trials assessing...
AbelZeta and AstraZeneca’s C-CAR031 Shows Promising Results in HCC Treatment
AbelZeta, a Sino-US biotech company with operations in Rockville, Maryland, and Shanghai, has presented data...
InnoCare’s Tafasitamab-Lenalidomide Combo on Track for Priority Review in China for DLBCL Treatment
The Center for Drug Evaluation (CDE) website has indicated that InnoCare (HKG: 9969; SHA: 688428),...
Jiangsu Hengrui Receives NMPA Approval to Begin Clinical Trials for New Anticancer Biologic
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Shenzhen Light and Biotechnology Partners with Shenzhen Increcare Biotech in IVD Sector
Shenzhen Light and Biotechnology Co., Ltd, a company based in China, has entered into a...